Meningococcal infection in Moscow: a ten-year observation (2014–2023)

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Attention to meningococcal infection (MI) continues unabated. The unique features of the disease are diverse, and some manifestations are extremely dangerous. In 2017, representatives of governments, global health organizations, public health authorities, academia, the private sector, and civil society called for combating meningococcal meningitis as a public health threat.

Objective. Characteristics of modern epidemic manifestations of MI in Moscow.

Materials and methods. An analysis of MI cases registered in Moscow from 2014 to 2023 and the results of studies of biomaterial from patients with the generalized MI forms was performed.

Results. A trend of increasing MI incidence in long-term dynamics with active change of serogroup landscape was revealed. Higher incidence among young people was established.

Conclusion. In order to strengthen population immunity, it is necessary to expand the regional vaccination calendar for additional vaccination of students of general education organizations from the 3rd to the 11th grade; first-year students of professional educational organizations and higher educational institutions.

Full Text

Restricted Access

About the authors

Irina S. Koroleva

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Author for correspondence.
Email: irina-korol@yandex.ru
ORCID iD: 0000-0003-0578-146X

МD, Head, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis

Russian Federation, Moscow

Maria I. Gritsay

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: maria-griz@mail.ru
ORCID iD: 0000-0002-6288-9074

Cand. Med. Sci., Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis

Russian Federation, Moscow

Maria А. Koroleva

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: korolevamaria389@gmail.com
ORCID iD: 0000-0002-2714-1191

МD, Senior Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis

Russian Federation, Moscow

Nadejda S. Churilova

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: n27101996@yandex.ru
ORCID iD: 0000-0001-5344-5829

Junior Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis

Russian Federation, Moscow

Grigoriy V. Beloshitsky

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: g-belosh1@yandex.ru
ORCID iD: 0000-0002-4769-3890

Cand. Med. Sci., Senior Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitis

Russian Federation, Moscow

Yulia V. Kobzeva

Moscow Office of Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: epid_otdel@mail.ru

Head, Epidemiological Surveillance Department

Russian Federation, Moscow

Daria Yu. Vasilevskaya

Moscow Office of Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: epid_otdel@mail.ru

Deputy Head, Epidemiological Surveillance Department

Russian Federation, Moscow

References

  1. European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases. https://atlas.ecdc.europa.eu/public/ index.aspx
  2. Public Health Agency of Canada. Notifiable Disease Charts. https://diseases.canada.ca/notifiable/charts-list
  3. Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance Reports. https://www.cdc.gov/meningococcal/surveillance/ index.html#enhanced-reports
  4. New Zealand Ministry of Health. Meningococcal Disease Reports. https://surv.esr.cri.nz/surveillance/Meningococcal_disease
  5. Thompson M.J., Ninis N., Perera R., Mayon-White R., Phillips C., Bailey L. et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet 2006; 367: 397–403. doi: 10.1016/S0140-6736(06)67932-4
  6. Beebeejaun K., Parikh S.R., Campbell H., Gray S., Borrow R., Ramsay M.E. et al. Invasive meningococcal disease: Timing and cause of death in England, 2008–2015. J. Infect. 2020; 80(3): 286–90. doi: 10.1016/j.jinf.2019.12.008
  7. Wang B., Santoreneos R., Giles L., Afzali H.H.A., Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine 2019; 37(21): 2768–82. DOI: 10.1016/ j.vaccine.2019.04.020
  8. Deghmane A.E., Taha S., Taha M.K. Global epidemiology and changing clinical presentations of invasive meningococcal disease: a narrative review. Infect. Dis. (Lond.) 2022; 54(1): 1–7. doi: 10.1080/23744235.2021.1971289
  9. Olbrich K.J., Müller D., Schumacher S., Beck E., Koerber E. Systematic Review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on Patients and Their Caregivers. Infect. Dis. Ther. 2018; 7: 421–38. doi: 10.1007/s40121-018-0213-2
  10. Koomen I., Raat H., Jennekens-Schinkel A., Grobbee D.E., Roord J.J., Roord J.J. et al. Academic and behavioral limitations and health-related quality of life in school age survivors of bacterial meningitis. Qual. Life Res. 2005; 14(6): 1563–72. doi: 10.1007/s11136-004-7706-z
  11. Christensen H., May M., Bowen L., Hickman V., Trotter C.L Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 2010; 10(12): 853–61. doi: 10.1016/S1473-3099(10)70251-6
  12. Wright C., Wordsworth R., Glennie L. Counting the Cost of Meningococcal Disease Scenarios of Severe Meningitis and Septicemia. Pediatr. Drugs. Paediatr Drugs. 2013;15(1): 49–58. doi: 10.1007/s40272-012-0006-0
  13. Darbà J., Kaskens L., Hark M., Wright C. Costs of surviving meningococcal disease in Spain: Evaluation for two cases of severe meningitis and septicaemia. Vaccine 2014; 32: 5006–12. doi: 10.1016/j.vaccine.2014.07.019
  14. World Health Organization. Defeating meningitis by 2030: a global road map. https://iris.who.int/bitstream/handle/10665/342010/9789240026407eng.pdf? sequence=1
  15. Лабораторная диагностика менингококковой инфекции и гнойных бактериальных менингитов: Методические указания МУК 4.2.1887-04. М., 2005. [Laboratory diagnosis of meningococcal infection and purulent bacterial meningitis: Methodological guidelines of MUC 4.2.1887-04]. Moscow, 2005. (In Russ.).
  16. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol. Rec. 2011; 86(47): 521–39. who-position-paper-on-meningococca-vaccine.pdf
  17. Лыткина И.Н., Чистякова Г.Г., Королева И.С. Профилактика бактериальных гнойных менингитов у детей в Москве. Новости вакцинопрофилактики. Вакцинация. Информационный бюллетень 1999; (2): 1–11. Lytkina I.N., Chistyakova G.G., Koroleva I.S. [Prevention of bacterial purulent meningitis in children in Moscow]. Vaccine prevention news. Vaccination. Information Bulletin 1999; (2): 1–11. (In Russ.).
  18. Booy R., Gentile A., Nissen M., Whelan J., Abitbo V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum. Vaccin Immunother. 2019; 15(2): 470–80. doi: 10.1080/21645515. 2018.1532248
  19. Potts C.C., Retchless A.C., McNamara L.A., Marasini D., Reese N., Swint S. et al. Acquisition of ciprofloxacin resistance among an expanding clade of β-lactamase– positive, serogroup Y Neisseria meningitidis in the United States. Clin. Infect. Dis. 2021; 73(7): 1185–93. doi: 10.1093/cid/ ciab358
  20. Ladhani S.N., Lucidarme J., Parikh S.R., Campbell Н., Borrow R., Ramsay M.E. et al. Meningococcal disease and sexual transmission: urogenital and anorectal infections and invasive disease due to Neisseria meningitidis. Lancet 2020; 395(10240): 1865–77. doi: 10.1016/S0140-6736(20)30913-2
  21. Костюкова Н.Н., Бехало В.А., Чернышова Т.Ф. Менингококковая инфекция в Российской Федерации: прошлое и ближайшие перспективы. Эпидемиол. инфекц. болезни. Актуал. вопр. 2014; (2): 73–9. Kostyukova N.N., Behal/o V.A., Chernyshova T.F. [Meningococcal infection in the Russian Federation: past and immediate prospects]. Epidemiology and infectious diseases. Сurrent items 2014; (2): 73–9. (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Long-term dynamics of HFMI incidence in Moscow population compared to the Russian Federation for the period from 2014 to 2023 The dotted lines indicate trend lines.

Download (89KB)
Indexing metadata
3. Fig. 2. Long-term incidence of HFMI in Moscow population by age

Download (213KB)
Indexing metadata
4. Fig. 3. Serogroup distribution of meningococcal strains isolated from patients with GFMI in Moscow in dynamics by year for 2014-2023.

Download (130KB)
Indexing metadata

Copyright (c) 2024 Bionika Media